363 related articles for article (PubMed ID: 34123366)
1. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.
Li L; Wang Z; Cui L; Xu Y; Guan K; Zhao B
Clin Transl Allergy; 2021 Jun; 11(4):e12038. PubMed ID: 34123366
[TBL] [Abstract][Full Text] [Related]
2. A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database.
Park S; Kim Y; Lee GH; Choi SA
Sci Rep; 2023 Oct; 13(1):17607. PubMed ID: 37848636
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
4. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
[TBL] [Abstract][Full Text] [Related]
5. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang M; Cheng Q; Shi X; Sun MH
Expert Opin Drug Saf; 2024 Mar; 23(3):353-362. PubMed ID: 37610085
[TBL] [Abstract][Full Text] [Related]
6. Anaphylaxis Associated With Allergen Specific Immunotherapy, Omalizumab, and Dupilumab: A Real World Study Based on the US Food and Drug Administration Adverse Event Reporting System.
Bian S; Zhang P; Li L; Wang Z; Cui L; Xu Y; Guan K; Zhao B; Chen Z
Front Pharmacol; 2021; 12():767999. PubMed ID: 34744748
[No Abstract] [Full Text] [Related]
7. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
8. Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration's adverse event reporting system (FAERS).
Pera V; Brusselle GG; Riemann S; Kors JA; Van Mulligen EM; Parry R; de Wilde M; Rijnbeek PR; Verhamme KMC
Front Pharmacol; 2023; 14():1276340. PubMed ID: 38035014
[No Abstract] [Full Text] [Related]
9. Biologics in allergic rhinitis.
Bayar Muluk N; Cingi C
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947
[TBL] [Abstract][Full Text] [Related]
10. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases.
Jackson K; Bahna SL
Expert Rev Clin Immunol; 2020 Mar; 16(3):311-319. PubMed ID: 31994421
[No Abstract] [Full Text] [Related]
11. Anaphylaxis to three humanized antibodies for severe asthma: a case study.
Jingo K; Harada N; Nishioki T; Torasawa M; Yamada T; Asao T; Takagi H; Takeshige T; Ito J; Takahashi K
Allergy Asthma Clin Immunol; 2020; 16():46. PubMed ID: 32536947
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma].
Zyryanov SK; Avdeev SN; Ivanov DA; Zhuravleva MV; Kniajeskaia NP; Matveev NV; Nenasheva NA; Fomina DS; Frolov MI
Ter Arkh; 2020 Dec; 92(12):172-179. PubMed ID: 33720591
[TBL] [Abstract][Full Text] [Related]
13. Is Omalizumab Related to Ear and Labyrinth Disorders? A Disproportionality Analysis Based on a Global Pharmacovigilance Database.
Park HT; Park S; Jung YW; Choi SA
Diagnostics (Basel); 2022 Oct; 12(10):. PubMed ID: 36292123
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia.
Ali A; García E; Torres-Duque CA; Rey D; Botero L; Saenz S; Avila MP; Mazo E; Londoño S
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):361-374. PubMed ID: 37994432
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps.
Koski RR; Hill L; Taavola K
J Pharm Technol; 2022 Oct; 38(5):289-296. PubMed ID: 36046351
[No Abstract] [Full Text] [Related]
16. Nonsteroidal Anti-inflammatory Drug (NSAID) Tolerance After Biological Therapy in Patients With NSAID-Exacerbated Respiratory Disease: A Randomized Comparative Trial.
Sánchez J; García E; Lopez JF; Calle A; Buendia JA
J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2172-2179. PubMed ID: 37146885
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Monoclonal Antibodies for Treatment of Uncontrolled Eosinophilic Asthma.
Koski RR; Grzegorczyk KM
J Pharm Pract; 2020 Aug; 33(4):513-522. PubMed ID: 31046541
[TBL] [Abstract][Full Text] [Related]
18. Biologics for asthma and risk of pneumonia.
Matera MG; Ora J; Calzetta L; Rogliani P; Cazzola M
J Asthma; 2024 Jan; ():1-7. PubMed ID: 38294705
[TBL] [Abstract][Full Text] [Related]
19. Exploring the risk of infection events in patients with asthma receiving
Giossi R; Pani A; Schroeder J; Scaglione F
Heliyon; 2024 Jan; 10(1):e23725. PubMed ID: 38268596
[TBL] [Abstract][Full Text] [Related]
20. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.
Charles D; Shanley J; Temple SN; Rattu A; Khaleva E; Roberts G
Clin Exp Allergy; 2022 May; 52(5):616-627. PubMed ID: 35174566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
